Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Given Consensus Rating of “Hold” by Analysts

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) have been assigned an average recommendation of “Hold” from the seven analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $48.00.

Several equities research analysts have recently commented on SNSE shares. Cantor Fitzgerald restated an “overweight” rating on shares of Sensei Biotherapeutics in a report on Thursday, June 4th. Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Citigroup initiated coverage on shares of Sensei Biotherapeutics in a report on Friday, May 22nd. They set a “buy” rating and a $55.00 price objective on the stock. Zacks Research raised shares of Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Finally, Leerink Partners initiated coverage on Sensei Biotherapeutics in a report on Monday, April 20th. They set an “outperform” rating and a $50.00 target price for the company.

Insider Activity at Sensei Biotherapeutics

In other news, major shareholder James Peyer sold 25,000 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the completion of the transaction, the insider directly owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Sensei Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its position in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares during the last quarter. Vivo Capital LLC bought a new position in shares of Sensei Biotherapeutics during the 1st quarter worth approximately $22,758,000. Finally, Stempoint Capital LP bought a new position in shares of Sensei Biotherapeutics during the 1st quarter worth approximately $4,188,000. Hedge funds and other institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Stock Performance

Sensei Biotherapeutics has a fifty-two week low of $5.86 and a fifty-two week high of $36.76. The firm’s 50 day simple moving average is $16.69 and its two-hundred day simple moving average is $19.62. The company has a market cap of $18.98 million, a PE ratio of -0.10 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($130.83).

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.